VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
VBIV was delisted on the 7th of August, 2024.
48 hedge funds and large institutions have $85.3M invested in VBI Vaccines, Inc. New Common Stock (Canada) in 2018 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 27 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
20% less funds holding
Funds holding: 60 → 48 (-12)
23% less capital invested
Capital invested by funds: $111M → $85.3M (-$26.1M)
44% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 27
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
+$2.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.05M |
| 3 |
Millennium Management
New York
|
+$928K |
| 4 |
GAI
General American Investors
New York
|
+$851K |
| 5 |
ECM
Element Capital Management
New York
|
+$836K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.31M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.33M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$1.72M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.3M |
| 5 |
HCM
Highbridge Capital Management
New York
|
-$875K |
VBIV Hedge Fund Activity: Q2 2018 in Review
48 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) for Q2 2018, worth a combined $85.3M — down 23% from $111M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of VBIV and 15 opened new positions — a net loss of 12 holders — while 9 trimmed existing stakes and 13 added.
The largest buyer was Menora Mivtachim Holdings, adding an estimated $2.4M. The largest seller was BlackRock, exiting entirely with an estimated $5.31M sold.
- 48 institutional investors held VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) as of Q2 2018, down from 60 in Q1 2018.
- Funds reported $85.3M of VBI Vaccines, Inc. New Common Stock (Canada) stock for Q2 2018, down 23% quarter-over-quarter.
- 15 funds opened new VBI Vaccines, Inc. New Common Stock (Canada) positions in Q2 2018 and 27 closed out, a net change of -12 holders.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) buyer in Q2 2018 was Menora Mivtachim Holdings, an estimated $2.4M added.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) seller in Q2 2018 was BlackRock, an estimated $5.31M sold.
Based on aggregated 13F filings for Q2 2018.